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Proteolytic processing of human prorenin in renal and non-renal
tissues. Previous studies have demonstrated that the mouse proprotein
convertase PCi (mPC1) accurately cleaves human prorenin to generate
active renin and that this processing event appears to require co-packaging
in secretory granules. In the current study, we have tested human PCi
(hPC1; also called PC3) for its ability to activate human prorenin. Our
results suggest that while hPC1 is capable of carrying out the specific
cleavage of human prorenin, it does so at a reduced efficiency as compared
to mPC1. This difference is due to sequences in the carboxy-terminus of
PCi as demonstrated by the activity of hybrid hPC1/mPC1 molecules.
These studies demonstrate that PCi cleavage of prorenin can occur in
humans and identify a functionally important region in the hPCi protein
for this interaction. Moreover, the localization of PCi in human tissues
suggests that it may participate in the generation of active renin in the
adrenal medulla and possibly in certain adrenal tumors.
Human renin is generated in vivo by proteolytic cleavage at a
pair of basic amino acids resulting in the removal of a 43 amino
acid prosegment from the amino terminus of prorenin [1]. In the
juxtaglomerular (JG) cells of the kidney, this activation step
occurs subsequent to intracellular targeting of prorenin to dense
core secretory granules [2]. Candidate prorenin processing en-
zymes (PPEs) would be expected, therefore, to cleave prorenin
with both site- and organelle-specificity. Previous studies have
suggested that both human cathepsin B and mouse PCi may meet
these criteria. Cathepsin B cleaves human prorenin in vitro with a
high affinity and site-selectivity and has been co-localized with
renin by immunocytochemistry in the dense core secretory gran-
ules of JG cells and human prolactinomas [3—6]. Using model
tissue culture systems, mouse PCi (mPC1) has also been shown to
cleave human prorenin with the expected site-specificity [7]. In
addition, this cleavage only takes place in cells containing secre-
tory granules [7]. In the current study, we have tested for the
ability of human PCi to cleave human prorenin in an effort to
determine whether it could play the role of a PPE in human
tissues.
Methods
Construction of expression vectors was carried out as previously
described [7]. Generation of the hybrid hPC1/mPC1 cDNA (h/rn
HYB1) was carried out by overlap extension PCR. The expressed
protein encodes a fusion protein consisting of the signal peptide
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and first 597 amino acids of hPC1 fused to amino acids 598-726 of
mPC1 [8]. Co-transfection of GH4C1 cells and determination of
secreted prorenin and active renin were also carried out as
previously described [7]. Briefly, GH4C1 cells were plated at a
density of 5 x iO cells/well in a six-well dish and were transfected
24 hours later with a calcium phosphate precipitate (300 j.d)
containing 1.2 .tg of an expression vector encoding human
prorenin (pRHR1100) and 4.8 g of the appropriate protease
expression vector. Twenty-four hours after transfection, the cells
were glycerol shocked and the medium was replaced with 2.0 ml
of fresh medium. Sixteen hours later, the medium was collected
and assayed for active renin and prorenin (trypsin-activatable
renin less active renin) using the angiotensin I generation assay.
Results
As previously reported [7], co-transfection of GH4C1 cells with
an expression vector encoding human prorenin and a neutral
plasmid (pUC18) leads to secretion of predominantly inactive
prorenin (Fig. 1, Cont.). However, when the human prorenin
expression vector is co-transfected with a vector encoding hPCi,
approximately 12% of the prorenin is converted to active renin
(Fig. 1, Native). Human prorenin containing mutations in either
the Lys or Arg residues at the cleavage site are not converted to
active renin by hPC1 (Fig. 1, K/A-2 and RJA-1). These results
suggest that hPC1, like mPC1, is capable of activating human
prorenin by specific cleavage at the pair of basic residues previ-
ously reported for cleavage in the human kidney [1].
Co-transfection of GH4C1 cells with the human prorenin
expression vector and either hPC1 or mPCi (Fig. 2) reveals that
mPC1 consistently generated more active human renin than hPC1
(31.2% vs. 12.3%, respectively, P < 0.001). Even though compar-
ison of the cDNAs encoding hPCi and mPC1 reveals that the two
proteases share an overall protein sequence homology of 92.6%
[8] amino acids 598-619 only display a 36% identity. To determine
whether the carboxy-terminal sequence differences between hPCi
and mPC1 might be responsible for the apparent difference in
prorenin processing activity, a hybrid PCi cDNA was constructed
which encodes the amino terminal 597 amino acids of hPC1 linked
to the carboxy-terminus (amino acids 598-726) of mPC1 (Fig. 2A,
h/rn HYB1). Co-expression of this hybrid PCi with human
prorenin leads to activation of human prorenin at an efficiency
comparable to that of mPC1 (26.2%; Fig. 2B). These results
suggest that the apparent human prorenin processing activity
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Fig. 1. Human PCi accurately processes human prorenin. Expression
vectors for either native human prorenin (Cont. and Native) or human
prorenin mutated at the native cleavage site (KIA-2 and R/A-1) were
co-transfected into GH4CI cells with either a control plasmid (pUC18;
Cont.) or an expression vector for hPC1 (Native, KJA-2 and R/A4).
Shown is the percent active renin (active renin/total renin) secreted.
Results represent the mean of 4 independent transfections.
differences between mPC1 and hPC1 are due to amino acids in
the carboxy-terminal 1/5 of the respective proteases.
Discussion
Significant differences exist in the processing events of pro-
renins from different tissues and species. Processing of prorenin in
the mouse submaxillasy gland (SMG) occurs at the analogous
position to that of human renin 191, but processing of rat renal
renin seems to occur after a threonine residue which is located 7
amino acids toward the carboxy terminus relative to the human
renin processing site [10, 111. The proteolytic cleavage site of
mouse renal prorenin is currently unknown. Rat renal renin and
mouse SMG renin (the product of the Ren-2 gene) subsequently
undergo an additional internal processing event, converting "one-
chain" active renin to a "two-chain" molecule [9—11] in which the
two halves are held together by a disulfide bridge. It is not yet
known whether mouse renal renin also undergoes a similar
secondary cleavage. Notably, while renal renins appear to be
processed within secretory granules, mouse SMG renin may be
processed to "one-chain" renin within the Golgi apparatus and
only a portion of the protein is further processed in granules to
yield the "two-chain" protein [121. Recently, two kallikrein-like
enzymes capable of processing mouse SMG prorenin have been
isolated from submaxillary glands [13, 14]. Notably, while these
enzyme are able to generate "one-chain" renin, they are unable to
carry out the second cleavage to yield the "two-chain" form [13].
In addition, kidney glandular kallikrein cannot activate mouse
SMG prorenin and PRECE (one of the SMG convertases) is
unable to activate mouse renal (Ren-1) or human prorenins [131.
Indeed, as of this date, there have been no published reports of
enzymes capable of activating either mouse renal prorenin
(Ren-1) or rat prorenin. Thus, while renins from mice, rats and
humans share many similarities in protein structure and function,
differences may exist in the way they are activated by processing
enzymes in different tissues.
PCi represents a candidate PPE with two important character-
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Fig. 2. Differences in cleavage efficiencies of mPCJ and hPC1. (A) Sche-
matic representation of the PCi proteins co-expressed with human
prorenin in GH4C1 cells. The hybrid PCi (h/rn HYB1) encodes aa 1-597
of hPC1 and aa 598-619 of mPC1. (B) Relative ability of the various PCi
proteins to cleave human prorenin. Results represent the mean of
4 independent transfections.
istics: the ability to carry out specific cleavage of human prorenin
and a seeming requirement for secretory granules in this process-
ing event. When tested in a similar co-transfection assay, human
cathepsin B has not demonstrated the ability to cleave human
prorenin (T.L. Reudeihuber and Chantal Mercure, unpublished
observation). Could PCi be the renal prorenin processing en-
zyme? It seems unlikely for two reasons: First, we have been
unable to detect immunoreactivity for hPC1 in human JG cells
although it does appear to be expressed in the adrenal medulla
where it may participate in prorenin activation in normal tissue
and in derived tumors such as pheochromocytomas (D. Ramla, T.
Reudelhuber M. Marcinciewicz and N. Seidah, submitted for
publication). Second, while mPC1 is able to cleave human prore-
nm and mouse SMG prorenin, it cannot activate mouse or rat
renal prorenin [7, 15]. Could the PPE in rodent and primate
kidneys differ? Injection of either mouse [16, 17] or rat [18]
embryos with the intact human prorenin gene results in the
generation of transgenic animals with active human renin in their
circulation. Thus, in spite of the apparent species selectivity of
PPE activities currently reported in vitro, mouse rat and human
kidneys should all express an enzyme(s) capable of activating
human prorenin. The role of cathepsin B and/or other endopro-
teases in the renal processing of prorenin remains an important
area of future investigation.
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